Vaccines provide unique benefits for human health, but two central technological challenges often limit their broad use:
1. Maintaining thermostability during transport and storage
2. The need to administer multiple doses to provide a robust immune response against infection or disease
VitriVax is revolutionizing the future of vaccines through our innovative Atomic Layering Thermostable Antigen and Adjuvant (ALTA™) platform technology. Our proprietary approach, ALTA™, leverages cutting-edge engineering to produce highly effective vaccines. VitriVax is dedicated to rigorous research and development that continuously advances our understanding of immune responses to create groundbreaking solutions. The ALTA™ technology ensures scalable manufacturing solutions for thermostable and single-dose vaccines. With a commitment to scientific excellence and public health, VitriVax is poised to redefine the future of vaccine technology.
Thermostability: Our spray drying technique encapsulates antigens in a sugar glass matrix for thermal and chemical protection, maintaining stability up to 70°C for extended periods without refrigeration.
Single-Shot Administration: We use atomic layer deposition (ALD) to coat spray-dried microparticles with nanometer-thick metal oxides, ensuring timed antigen/adjuvant release for up to six months post-injection.
ALTA™ uses highly scalable, commercially available equipment and ingredients already common in pharmaceuticals and generally recognized as safe (GRAS).
ALTA™ vaccines are designed for long-term storage and ease of transport worldwide, including for emergency and military use. They increase vaccination adherence through a single-dose format and can reach remote areas due to minimal cold chain needs, thereby contributing to disease prevention and saving lives.